Eric Simpson, MD, MCR

Raj J. Chovatiya, MD, PhD; Alexandra K. Golant, MD; Eric Simpson, MD, MCR; and Linda Stein Gold, MD, share clinical pearls and discuss the future treatment landscape for atopic dermatitis.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss challenges adolescent and adult patients face with current oral and topical therapies and optimizing disease management.

Experts in the management of atopic dermatitis assess the use of JAK inhibitors in clinical practice and considerations for treatment selection for patients with atopic dermatitis.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.

Drs Alexandra K. Golant, Raj J. Chovatiya, Linda Stein Gold, and Eric Simpson comment on clinical implications of boxed warnings for the utilization of JAK inhibitors when treating atopic dermatitis.

Eric Simpson, MD, MCR, leads a discussion on current FDA approved topical and systemic JAK inhibitors for the management of atopic dermatitis.

Alexandra K. Golant, MD, highlights factors to consider when recommending the use of JAK inhibitors to manage atopic dermatitis for various patient populations.

Raj J. Chovatiya, MD, PhD, provides an overview of JAK inhibitors and their use in atopic dermatitis treatment.

Alexandra K. Golant, MD; Raj. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss goals of therapy for patients with atopic dermatitis and challenges physicians face in management of the disease.

Eric Simpson, MD, MCR, reviews conventional topical and systemic therapy treatment options for the management of atopic dermatitis.

Drs Eric Simpson, Alexandra K. Golant, and Raj J. Chovatiya share their approaches to atopic dermatitis care.

Raj J. Chovatiya, MD, PhD, comments on the impact of atopic dermatitis on the quality of life for patients and their families.